Join Biocytogen at MSD(Merck) technology symposium

Biocytogen is excited to announce our participation in the MSD Technology Symposium 2024, taking place from September 24-25 at the Greater Philadelphia Expo Center in Oaks, PA. As pioneers in antibody discovery and gene-editing technologies, we look forward to engaging with scientists, industry professionals, and innovators to explore the latest advancements in biotechnology. This symposium provides a valuable opportunity to discuss breakthrough research, share knowledge, and foster collaborations that can drive future innovations. We hope to connect with you there!

What is MSD?

The  MSD Technology Symposium is the company’s flagship live event, attracting over 1,500 scientists and more than 85 external vendors. It serves as a platform to showcase advancements in therapeutic approaches, cutting-edge technologies, and strategies for speeding up the delivery of medicines to patients.

Event Overview 

Time: September 24-25, 2024

Location: Greater Philadelphia Expo Center, Oaks, PA (US)

The 2024 Technology Symposium, now in its 28th year, will celebrate advancements in science, technology, and innovation while fostering critical thinking to inspire ideas on applying cutting-edge technologies to meet future needs. This year emphasizes in-person participation, with select components available for virtual viewing after the event.

Featuring the theme “Technology & Data Inspiring Action Towards a Better Future,” the program includes a variety of engaging activities, such as a Fireside Chat, TED-style talks, an Innovation Awards Ceremony, hundreds of posters, and over 100 exhibitors showcasing the latest products.

About BIOCYTOGEN

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg). 

We look forward to seeing you at the at MSD(Merck) technology symposium!